Molecular mechanisms of renal fibrosis

Project: Research

Status	Finished
Effective start/end date	1/01/10 → 31/12/12

Anti-fibrotic actions of relaxin
Samuel, C. S., Royce, S. G., Hewitson, T. D., Denton, K. M., Cooney, T. E. & Bennett, R. G., 1 May 2017, In: British Journal of Pharmacology. 174, 10, p. 962-976 15 p.
Research output: Contribution to journal › Review Article › Research › peer-review

105 Citations (Scopus)
The anti-fibrotic actions of relaxin are mediated through a NO-sGC-cGMP-dependent pathway in renal myofibroblasts in vitro and enhanced by the NO donor, diethylamine NONOate
Wang, C., Kemp-Harper, B. K., Kocan, M., Ang, S. Y., Hewitson, T. D. & Samuel, C. S., 31 Mar 2016, In: Frontiers in Pharmacology. 7, 12 p., 91.
Research output: Contribution to journal › Article › Research › peer-review

Open Access
File

35 Citations (Scopus)
Relaxin requires the angiotensin II type 2 receptor to abrogate renal interstitial fibrosis
Chow, B. SM., Kocan, M., Bosnyak, S., Sarwar, M., Wigg, B., Jones, E. S., Widdop, R. E., Summers, R. J., Bathgate, R. A. D., Hewitson, T. D. & Samuel, C. S., 2014, In: Kidney International. 86, 1, p. 75 - 85 11 p.
Research output: Contribution to journal › Article › Research › peer-review

100 Citations (Scopus)

Project Details